The Role of HER3 Expression in Advanced Solid Tumors

The Role of HER3 Expression in Advanced Solid Tumors

The Role of HER3 Expression in Advanced Solid Tumors
RestartResume

Meet HER3, the underappreciated sibling of HER that contributes to worse prognoses and therapy resistance in solid tumors but is also now a target!

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies. 

    *Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lauren Ritterhouse, MD,vPhD
    Associate Director
    Center for Integrated Diagnostics
    Assistant Professor, Harvard Medical School
    Massachusetts General Hospital
    Boston, MA

    Consulting Fees: Amgen, Loxo Oncology, Merck, and NuProbe

    Faculty:
    Pasi A. Jänne, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Boston, MA

    Consulting Fees: AbbVie, Accutar Biotech, ACEA Biosciences, Allorion Therapeutics, Araxes Pharma, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals, Daiichi Sankyo, Eli Lilly Pharmaceuticals, Esai, Ignyta, Loxo Oncology, Mirati Therapeutics, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta, Voronoi
    Contracted Research: Astellas Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Pharmaceuticals, PUMA, Revolution Medicines, Takeda Oncology
    Stock Ownership: Gatekeeper Pharmaceuticals
    Patents, Royalities, other Intellectual Property: Labcorp - This is for post-marketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp.

    Kanwal Raghav, MBBS, MD
    Associate Professor
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Contracted Research: Bayer, Daiichi Sankyo, Genentech, Guardant, Merck
    Consulting Fees: AZD, Bayer, Daiichi Sankyo, Eisai

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN has nothing to disclose.
    • Anna Trentini has nothing to disclose
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe the biology of HER3 and its role in oncogenesis
    2. Establish the optimal use of molecular/biomarker/genomic testing for HER3 expression in patients with solid metastatic tumors
    3. Evaluate recent clinical trial data examining the safety and efficacy of HER3-targeted therapies in treating metastatic solid tumors, including EGFR TKI-resistant NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of community and academic oncologists and pathologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this audio-based activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free